| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.200 | Biomarker | disease | BEFREE | However, aromatase inhibitors cause major side effects such as bone loss and abnormal lipid metabolism, due to indiscriminate reduction of aromatase activity in all expression sites of the body. | 18614276 | 2009 | ||||
|
0.200 | Biomarker | disease | BEFREE | In fact, therapy with aromatase inhibitors is associated with bone loss and fractures. | 15794932 | 2005 | ||||
|
0.200 | Biomarker | disease | BEFREE | Aromatase inhibitors target the production of estrogen in breast adipose tissue, but in doing so, also decrease estrogen formation in bone and other sites, giving rise to deleterious side effects, such as bone loss and arthralgia. | 16357189 | 2005 | ||||
|
0.200 | GeneticVariation | disease | BEFREE | Perimenopausal bone mass or bone loss in untreated women was not associated with the CYP19 polymorphisms. | 14517714 | 2004 | ||||
|
0.200 | GeneticVariation | disease | BEFREE | However, a significant association was observed between the CYP19 genotype and BMD change at the distal forearm; the highest bone loss was observed in subjects homozygotic for the shortest observed allele length of (TTTA)(7)-repeats (P < 0.02). | 12843146 | 2003 | ||||
|
0.200 | GeneticVariation | disease | BEFREE | Thus, a male carrying homozygous mutations in the ER-alpha gene and two males with homozygous mutations in the aromatase gene had osteopenia, unfused epiphyses, and elevated indices of bone turnover. | 11730247 | 2001 | ||||
|
0.200 | GeneticVariation | disease | BEFREE | Inactivating mutations of the aromatase gene are associated with decreased bone mineral density in both men and women. | 11344237 | 2001 | ||||
|
0.200 | GeneticVariation | disease | BEFREE | Estrogen and the estrogen receptor (ER) play a central role in bone metabolism as illustrated by the loss of bone mass after menopause and the osteopenia in individuals with defect aromatase or ER. | 11092403 | 2000 | ||||
|
0.200 | Biomarker | disease | HPO |